These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 24486586)

  • 1. Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.
    Garcia-Gomez A; Quwaider D; Canavese M; Ocio EM; Tian Z; Blanco JF; Berger AJ; Ortiz-de-Solorzano C; Hernández-Iglesias T; Martens AC; Groen RW; Mateo-Urdiales J; Fraile S; Galarraga M; Chauhan D; San Miguel JF; Raje N; Garayoa M
    Clin Cancer Res; 2014 Mar; 20(6):1542-54. PubMed ID: 24486586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
    Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
    Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
    Engür S; Dikmen M
    Acta Clin Belg; 2017 Dec; 72(6):391-398. PubMed ID: 28327055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
    Lee EC; Fitzgerald M; Bannerman B; Donelan J; Bano K; Terkelsen J; Bradley DP; Subakan O; Silva MD; Liu R; Pickard M; Li Z; Tayber O; Li P; Hales P; Carsillo M; Neppalli VT; Berger AJ; Kupperman E; Manfredi M; Bolen JB; Van Ness B; Janz S
    Clin Cancer Res; 2011 Dec; 17(23):7313-23. PubMed ID: 21903769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
    Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
    Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells.
    Augello G; Modica M; Azzolina A; Puleio R; Cassata G; Emma MR; Di Sano C; Cusimano A; Montalto G; Cervello M
    Cell Death Dis; 2018 Jan; 9(2):28. PubMed ID: 29348495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
    Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
    Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells.
    Engür S; Dikmen M; Öztürk Y
    Immunopharmacol Immunotoxicol; 2016; 38(2):87-97. PubMed ID: 26667773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
    Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
    Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
    Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
    Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixazomib for the treatment of multiple myeloma.
    Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
    Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.
    Garcia-Gomez A; Ocio EM; Crusoe E; Santamaria C; Hernández-Campo P; Blanco JF; Sanchez-Guijo FM; Hernández-Iglesias T; Briñón JG; Fisac-Herrero RM; Lee FY; Pandiella A; San Miguel JF; Garayoa M
    PLoS One; 2012; 7(4):e34914. PubMed ID: 22539950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
    Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
    Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
    Kupperman E; Lee EC; Cao Y; Bannerman B; Fitzgerald M; Berger A; Yu J; Yang Y; Hales P; Bruzzese F; Liu J; Blank J; Garcia K; Tsu C; Dick L; Fleming P; Yu L; Manfredi M; Rolfe M; Bolen J
    Cancer Res; 2010 Mar; 70(5):1970-80. PubMed ID: 20160034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models.
    Gu JJ; Hernandez-Ilizaliturri FJ; Mavis C; Czuczman NM; Deeb G; Gibbs J; Skitzki JJ; Patil R; Czuczman MS
    Anticancer Drugs; 2013 Nov; 24(10):1030-8. PubMed ID: 23995855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.
    Ravi D; Beheshti A; Abermil N; Passero F; Sharma J; Coyle M; Kritharis A; Kandela I; Hlatky L; Sitkovsky MV; Mazar A; Gartenhaus RB; Evens AM
    Cancer Res; 2016 Jun; 76(11):3319-31. PubMed ID: 26988986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral ixazomib maintenance therapy in multiple myeloma.
    Offidani M; Corvatta L; Gentili S; Maracci L; Leoni P
    Expert Rev Anticancer Ther; 2016; 16(1):21-32. PubMed ID: 26588946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.
    Tian Z; Zhao JJ; Tai YT; Amin SB; Hu Y; Berger AJ; Richardson P; Chauhan D; Anderson KC
    Blood; 2012 Nov; 120(19):3958-67. PubMed ID: 22983447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.
    Paulus A; Masood A; Miller KC; Khan AN; Akhtar D; Advani P; Foran J; Rivera C; Roy V; Colon-Otero G; Chitta K; Chanan-Khan A
    Br J Haematol; 2014 Apr; 165(1):78-88. PubMed ID: 24467634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
    Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
    Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.